A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 152
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : TG
Long Form : 6-thioguanine
No. Year Title Co-occurring Abbreviation
2021 Adsorption behavior of mercaptopurine and 6-thioguanine drugs on the B12N12, AlB11N12 and GaB11N12 nanoclusters, a comparative DFT study. DFT, MC, QMAIM
2021 FANCD2-Associated Nuclease 1 Partially Compensates for the Lack of Exonuclease 1 in Mismatch Repair. FAN1, MMR, MNU
2021 Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study. 6-MP, ALL, CI, IQR, MTX
2021 Understanding thiopurine methyltransferase polymorphisms for the targeted treatment of hematologic malignancies. ALL, MP, TPMT
2020 A Nucleotide Analog Prevents Colitis-Associated Cancer via Beta-Catenin Independently of Inflammation and Autophagy. AOM, CAC, DSS, IBD, WT
2020 Development of 6-Thioguanine conjugated PLGA nanoparticles through thioester bond formation: Benefits of electrospray mediated drug encapsulation and sustained release in cancer therapeutic applications. ---
2020 Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom. AZA, IBD, MP, NRH
2020 The continuous rediscovery and the benefit-risk ratio of thioguanine, a comprehensive review. AZA, IBD, MP, NRH, SLE
2019 Hexagonal boron nitride nanosheet as novel drug delivery system for anticancer drugs: Insights from DFT calculations and molecular dynamics simulations. BN, DFT, DOS, EDA, FU, MD, MP, NCI, QTAIM
10  2019 Nucleobase derivatives induce in-source decay of oligonucleotides as new matrix-assisted laser desorption/ionization matrices. LC/MS, MALDI-TOF MS
11  2018 Assessment of the chitosan-functionalized graphene oxide as a carrier for loading thioguanine, an antitumor drug and effect of urea on adsorption process: Combination of DFT computational and molecular dynamics simulation studies. DFT, GO, MD
12  2018 Magnetic molecularly imprinted polymer nanoparticles for simultaneous extraction and determination of 6-mercaptopurine and its active metabolite thioguanine in human plasma. 6-MP, MMI-SPE
13  2018 Methotrexate and Thioguanine Rescue Therapy for Conventional Thiopurine Failing Ulcerative Colitis Patients: A Multi-center Database Study on Tolerability and Effectiveness. MTX, UC
14  2017 Construction of 6-thioguanine and 6-mercaptopurine carriers based on betacyclodextrins and gold nanoparticles. beta-CD, MP, PAMPA
15  2017 Thioguanine in inflammatory bowel disease: Long-term efficacy and safety. anti-TNF, CD, IBD, MRI, NRH, UC
16  2016 Colonic microbiota can promote rapid local improvement of murine colitis by thioguanine independently of T lymphocytes and host metabolism. MP, TGN, WT
17  2015 Safety of Tioguanine During Pregnancy in Inflammatory Bowel Disease. 6-TGN, IBD
18  2015 Tubulin structure-based drug design for the development of novel 4beta-sulfur-substituted podophyllum tubulin inhibitors with anti-tumor activity. GTP, ITC, MP, PTOX
19  2014 Splitting a therapeutic dose of thioguanine may avoid liver toxicity and be an efficacious treatment for severe inflammatory bowel disease: a 2-center observational cohort study. UC
20  2013 Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy. AZA, IBD, MP, NRH
21  2012 Thiopurine methyltransferase predicts the extent of cytotoxicty and DNA damage in astroglial cells after thioguanine exposure. DSBs, SSBs, Tpmt
22  2012 Tioguanine in the treatment of refractory coeliac disease--a single centre experience. ---
23  2011 Liquid chromatography-tandem mass spectrometry quantification of 6-thioguanine in DNA using endogenous guanine as internal standard. ---
24  2011 Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia. EFS, MP, OR
25  2011 New Nanomedicine Approaches Using Gold-thioguanine Nanoconjugates as Metallo-ligands. ---
26  2011 Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk. 6-MP, AZA, IBD, TPMT
27  2010 Antimicrobial and anticancer efficacy of antineoplastic agent capped gold nanoparticles. FTIR
28  2010 In vivo 6-thioguanine-resistant T cells from melanoma patients have public TCR and share TCR beta amino acid sequences with melanoma-reactive T cells. HPRT, TRB, WT
29  2010 Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial. CCG-1952, EFS, IT-MTX, ITT, MP, RHR, VOD
30  2008 Clonal expansions of 6-thioguanine resistant T lymphocytes in the blood and tumor of melanoma patients. CDR3, HPRT, LNs, TCR
31  2007 The effect of dietary folic acid deficiency on the cytotoxic and mutagenic responses to methyl methanesulfonate in wild-type and in 3-methyladenine DNA glycosylase-deficient Aag null mice. MMS
32  2006 Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942). ALL, CCG, CIVI, CSF, MP, VOD
33  2004 Mismatch repair and DNA damage signalling. ATM, ATR, HR, IR, MMR
34  2004 Mutation carrier testing in Lesch-Nyhan syndrome families: HPRT mutant frequency and mutation analysis with peripheral blood T lymphocytes. HPRT
35  2004 Portal hypertension develops in a subset of children with standard risk acute lymphoblastic leukemia treated with oral 6-thioguanine during maintenance therapy. ALL, MP, PH
36  2003 Combination therapy in childhood leukaemia: in vitro studies of thiopurines and inhibitors of purine metabolism on apoptosis. 6-MP, MTX, PI, TF
37  2003 Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92. ALL, MP, TGNs
38  2003 Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. AZA, MP
39  2002 Childhood hyperuricemia and acute renal failure resulting from a missense mutation in the HPRT gene. ARF, HPRT
40  2002 Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia. MP, TGN
41  2002 Mercaptopurine metabolite results in clinical gastroenterology practice. AZA, MMP, MP
42  2002 Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. 6-MP, tXMP
43  2001 Deoxythioguanosine triphosphate impairs HIV replication: a new mechanism for an old drug. RT
44  2001 Molecular dynamics of DNA quadruplex molecules containing inosine, 6-thioguanine and 6-thiopurine. tI
45  2001 Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study. ALL, CIVI, MP, TGN
46  2000 Azathioprine associated T-cell mutations in insulin-dependent diabetes mellitus. HPRT, IDDM, MFs
47  2000 Bromodeoxyuridine labelling as an alternative method to identify 6-thioguanine-resistant mutant lymphocytes in humans. anti-BrdU, TGr
48  1999 Microsatellite instability is co-selectable with gene amplification in a mammalian mutator phenotype. PALA
49  1998 Spectrum of point mutations in the coding region of the hypoxanthine-guanine phosphoribosyltransferase (hprt) gene in human T-lymphocytes in vivo. HPRT
50  1998 Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations. MP, TGN
51  1997 A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion. ALL, CIV
52  1997 Nitrogen mustard-mediated mutagenesis in human T-lymphocytes in vitro. HPRT, MF
53  1996 Mutagenesis of AS52 cells by low concentrations of lead(II) and mercury(II) gpt
54  1996 Reduced proliferation rate of hypoxanthine-phosphoribosyl transferase mutant human T-lymphocytes in vitro. CE, HPRT, MF
55  1996 Somatic mutations are frequent and increase with age in human kidney epithelial cells. ---
56  1995 Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. MP, TGMP, TGN, TIMP, TPMT
57  1994 Detection of opiate-enhanced increases in DNA damage, HPRT mutants, and the mutation frequency in human HUT-78 cells. EMS, MF, MGE, SSCP
58  1994 Influence of PHA stimulation on the cytotoxicity and mutagenicity of X-rays and ethylnitrosourea in human peripheral blood T-lymphocytes. ENU
59  1994 The cytotoxicity of thioguanine vs mercaptopurine in acute lymphoblastic leukemia. ALL, MP
60  1993 Hprt activities and RNA phenotypes in 6-thioguanine resistant human T-lymphocytes. HPRT
61  1993 Hypoxanthine phosphoribosyl transferase assay of lead mutagenicity on keratinocytes. HPRT
62  1993 Spectrum of spontaneous mutation in animal cells containing an aphidicolin-resistant DNA polymerase alpha. HPRT, PCR
63  1992 A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. AML, CA, CR, DNR, IDR
64  1992 Mechanisms of resistance to 6-thioguanine in a murine pancreatic tumor. ---
65  1992 Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance. AG, CCNU, FUHU, GM, NU, PCB, PR, RT, SD
66  1991 Induction of 6-thioguanine-resistant lymphocytes in Fischer 344 rats following in vivo exposure to N-ethyl-N-nitrosourea and cyclophosphamide. CEs, CP, ENU, PHA, TGr
67  1991 Nitroreduction is not involved in the genotoxicity of 2-nitropropane in cultured mammalian cells. 2-NP, IPHA
68  1991 Selective inhibition of sequence-specific protein-DNA interactions by incorporation of 6-thioguanine: cleavage by restriction endonucleases. ---
69  1990 Characterization of the DNA damage in 6-thioguanine-treated cells. CHO, SSB
70  1990 Cytotoxic and mutagenic effect of UV, ethylnitrosourea and (+/-)-7 beta,8 alpha-dihydroxy-9 alpha,10 alpha-epoxy-7,8,9,10-tetrahydrobenzo [a]pyrene in diploid human T lymphocytes in culture: comparison with fibroblasts. BPDE, ENU
71  1990 Increased frequency of 6-thioguanine-resistant peripheral blood lymphocytes in Werner syndrome patients. WS
72  1990 Inhibition of c-myc expression in human promyelocytic leukemia and colon adenocarcinoma cells by 6-thioguanine. GM-CSF, HPRT, TGMP
73  1990 Involvement of different pathways in the genotoxicity of nitropropanes in cultured mammalian cells. 1-NP, 2-NP
74  1990 Modulation of the cytotoxic mechanism of 6-thioguanine by 4-amino-5-imidazolecarboxamide. AIC
75  1990 Multiple small exposures of filtered mid-UV radiation increase the resistance of Chinese hamster cells to far-UV, mid-UV and filtered mid-UV radiation. HGPRT
76  1990 Mutagenicity of nitrite-treated soy sauce in Chinese hamster V79 cells. ---
77  1990 The mutation of V79 cells by N-nitrosobis(2-oxopropyl)amine activated by pancreas acinar and duct tissue from Syrian hamsters and MRC-Wistar rats. ---
78  1989 A chromosome study of 6-thioguanine-resistant mutants in T lymphocytes of Hiroshima atomic bomb survivors. HPRT, TGr
79  1989 Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. AMSA, ANLL, APL, ara-C, CR, DNR
80  1989 Association of decreased intercellular communication with the immortal but not the tumorigenic phenotype in human mammary epithelial cells. HMEC, TGr, TGs
81  1989 H4IIEC3 rat hepatoma cells activate N-nitrosodimethylamine but are resistant to the genotoxic products. NDMA
82  1989 Hprt mutations and karyotype abnormalities in T-cell clones from healthy subjects and melphalan-treated ovarian carcinoma patients. HPRT
83  1989 Prediction of thioguanine-induced cytotoxicity by dual-parameter flow cytometric analysis. ---
84  1989 [Incidence of somatic mutations of the lymphocytes in subjects working in an environment with cancer risk]. HPRT
85  1988 A sensitive assay for 6-thioguanine-resistant lymphocytes. CB
86  1988 Calmodulin involvement in TPA and DDT induced inhibition of intercellular communication. CaM, CzM, TPA
87  1988 Chemotherapeutic evaluation using clinical criteria in spontaneous, autochthonous murine breast tumors. FUra
88  1988 Enhanced mitogenic responsiveness to granulocyte-macrophage colony-stimulating factor in HL-60 promyelocytic leukemia cells upon induction of differentiation. DMSO, GM-CSF
89  1988 Phase I/pharmacokinetic study of thioguanine administered as a 48-hour continuous intraperitoneal infusion. HPLC, i.p, MR, MTD, PR
90  1988 Short-term therapy for acute myelogenous leukemia. ADR, CR
91  1987 Cloned mouse lymphocytes permit analysis of somatic mutations that occur in vivo. HPRT
92  1987 Comparison of in vivo and in vitro effects of continuous exposure of L1210 cells to 6-thioguanine. ---
93  1987 Effects of incorporation of 6-thioguanine into SV40 DNA. ---
94  1987 Factors that affect the frequency of thioguanine-resistant lymphocytes in mice following exposure to ethylnitrosourea. ENU
95  1987 Refinement of a T-lymphocyte cloning assay to quantify the in vivo thioguanine-resistant mutant frequency in humans. HPRT, TCGF
96  1986 Concurrent unilateral chromatid damage and DNA strand breakage in response to 6-thioguanine treatment. CHO, PCC
97  1986 Fibroblasts from patients with inherited predisposition to retinoblastoma exhibit normal sensitivity to the mutagenic effects of ionizing radiation. Rb
98  1986 Formation of 6-thioguanine and 6-mercaptopurine from their 9-alkyl derivatives in mice. MP
99  1986 Inhibition of metabolic cooperation in Chinese hamster V79 cells by 1 alpha, 25-dihydroxycholecalciferol, the active metabolite of vitamin D3. PDBu, PMA
100  1985 A method to quantify spontaneous and in vivo induced thioguanine-resistant mouse lymphocytes. HPRT